Overview

A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

Status:
Not yet recruiting
Trial end date:
2024-03-18
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety and tolerability of single doses of REGN7508 in healthy adult participants The secondary objectives of the study are to: - Evaluate the effects of single doses of REGN7508 on intrinsic/common pathway coagulation - Evaluate the effects of single doses of REGN7508 on extrinsic/common pathway coagulation - Characterize the drug concentration profiles and pharmacokinetics (PK) following single escalating doses of REGN7508 - Characterize the concentration profiles of total Factor XI (FXI) following single escalating doses of REGN7508 - Assess the immunogenicity of single doses of REGN7508
Phase:
Phase 1
Details
Lead Sponsor:
Regeneron Pharmaceuticals